Article Text
Abstract
Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should be managed differently from standard practices adapted for younger populations has not yet been defined. In this article, we provide an overview of ethical and practical challenges in preparing for a genetic study of over 14 000 healthy Australians aged 70 years or older enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank. At the time of consent, all participants in this study were free of life-threatening illness, cardiovascular disease or cognitive impairment. ASPREE is thus a cohort of healthy elderly individuals with seemingly minimal burden of genetic disease recruited without ascertainment bias. The cohort presents a unique opportunity to address the penetrance of known pathogenic variants in a population without disease symptoms; however, it also raises a number of ethical concerns regarding the interpretation and disclosure of variants with known clinical actionability. Some of the challenges include (a) how to manage the interpretation, disclosure and actioning of pathogenic variants found in otherwise healthy elderly adults without disease symptoms, (b) whether or not to disclose findings for the benefit of family members rather than elderly consented donors themselves, (c) how to manage the return of genetic findings to the elderly individuals who are now in severe cognitive decline or terminal illness, (d) how to ensure quality of information and clinical service upon disclosure of results to this demographic and (e) how to prepare for the insurance implications of disclosing genetic information under Australian law. We discuss these and other dilemmas and propose a defensible plan of management.
Trial registration number ISRCTN83772183
- Genetic Counselling/Prenatal Diagnosis
- Genetic Information
- Genethics
- Genetic Screening/Testing
- Elderly and Terminally Ill
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Footnotes
Twitter Follow Paul Lacaze @PaulLacaze
Contributors PL wrote the manuscript and provided the intellectual conception of the article. RW and JM made substantial contributions to the conception and design of the work. JR and IW were critical in providing intellectual input and drafting and revising the article.
Competing interests None declared.
Ethics approval The Alfred Hospital Office of Ethics and Research Governance.
Provenance and peer review Commissioned; externally peer reviewed.
Other content recommended for you
- Protective lipid-lowering variants in healthy older individuals without coronary heart disease
- Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders
- Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study
- Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada
- Clinical application of fetal genome-wide sequencing during pregnancy: position statement of the Canadian College of Medical Geneticists
- Guideline for feedback of individual genetic research findings for genomics research in Africa
- Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel
- AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol
- Structural Aberrations with Secondary Implications (SASIs): consensus recommendations for reporting of cancer susceptibility genes identified during analysis of Copy Number Variants (CNVs)
- Taking it to the bank: the ethical management of individual findings arising in secondary research